Review Article
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
Table 2
Adjuvant therapy versus placebo.
| | Pramipexole | Ropinirole | Pergolide* | Bromocriptine | Cabergoline |
| Off-time reduction (h/day) | −1.81 | −0.93 | −1.60 | −1.78 | −1.29 | LEDD red (mg/day) | −114.82 | −119.81 | −183.90 | −52.17 | −149.60 | UPDRS ADL reduction (pts) | | | | | −1.78 | UPDRS III reduction (pts) | | −4.80 | | | −1.74 | Incidence of dyskinesia (OR) | 2.63 | 3.21 | 4.64 | 2.52 | 1.44 |
|
|
*Based on data from just one trial [71].
|